Leerink Partnrs Issues Pessimistic Outlook for BBIO Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Investment analysts at Leerink Partnrs dropped their Q4 2024 earnings per share estimates for BridgeBio Pharma in a research note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($1.07) per share for the quarter, down from their previous forecast of ($1.06). The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($2.56) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma’s FY2025 earnings at ($2.77) EPS, FY2026 earnings at ($1.00) EPS, FY2027 earnings at $1.61 EPS, FY2028 earnings at $4.55 EPS and FY2029 earnings at $5.78 EPS.

Several other analysts have also issued reports on the company. Scotiabank upped their target price on BridgeBio Pharma from $45.00 to $48.00 and gave the stock a “sector outperform” rating in a research note on Monday, November 25th. Oppenheimer initiated coverage on BridgeBio Pharma in a research note on Thursday, October 3rd. They issued a “market perform” rating for the company. Evercore ISI upped their target price on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research note on Monday, December 23rd. Leerink Partners cut their target price on BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. Finally, HC Wainwright reissued a “buy” rating and set a $49.00 price objective on shares of BridgeBio Pharma in a research note on Monday, December 16th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $48.08.

BridgeBio Pharma Price Performance

Shares of BBIO opened at $35.84 on Thursday. The firm has a market cap of $6.77 billion, a P/E ratio of -14.87 and a beta of 1.05. The stock has a 50 day simple moving average of $28.27 and a two-hundred day simple moving average of $26.74. BridgeBio Pharma has a 1 year low of $21.62 and a 1 year high of $41.04.

Insider Activity at BridgeBio Pharma

In other BridgeBio Pharma news, CFO Brian C. Stephenson sold 4,156 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total transaction of $93,135.96. Following the completion of the transaction, the chief financial officer now owns 93,758 shares of the company’s stock, valued at approximately $2,101,116.78. This trade represents a 4.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Neil Kumar sold 27,389 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total transaction of $613,787.49. Following the completion of the sale, the chief executive officer now directly owns 4,897,443 shares in the company, valued at $109,751,697.63. This represents a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 24.66% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On BridgeBio Pharma

A number of hedge funds have recently bought and sold shares of the company. Janus Henderson Group PLC lifted its stake in shares of BridgeBio Pharma by 11.7% in the third quarter. Janus Henderson Group PLC now owns 4,818,012 shares of the company’s stock worth $122,658,000 after buying an additional 505,481 shares in the last quarter. Frazier Life Sciences Management L.P. raised its holdings in BridgeBio Pharma by 3.5% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 3,760,457 shares of the company’s stock worth $95,741,000 after acquiring an additional 127,853 shares during the last quarter. Geode Capital Management LLC lifted its position in BridgeBio Pharma by 3.8% in the 3rd quarter. Geode Capital Management LLC now owns 3,413,949 shares of the company’s stock valued at $86,936,000 after acquiring an additional 123,540 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in BridgeBio Pharma by 40.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,534,972 shares of the company’s stock valued at $38,881,000 after purchasing an additional 442,248 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of BridgeBio Pharma by 8.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,284,802 shares of the company’s stock worth $32,711,000 after purchasing an additional 95,605 shares in the last quarter. Institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.